Cal/BD treatment suppresses epidermal and dermal infiltration of pathogenic CD8 + T cell populations, including IFN-γ–producing CD8 + T cells (CD8 + IFN-γ +) and tissue-resident memory T cells (TRM; CD8 + CD103 +), while concurrently reducing myeloperoxidase-positive (MPO +) neutrophils—key contributors to IL-17–driven inflammation. The gene discussed is CD8A; the disease is Behcet disease.